← Back to guidelines
Allergy & Immunology165 papers

Parasympathetic ganglion injury

Last edited: 4/15/2026

Overview

Parasympathetic ganglion injury primarily affects structures like the ciliary ganglion, leading to dysfunction in parasympathetic innervation to the eye, often manifesting as issues with pupil constriction and lens accommodation. The molecular mechanisms underlying cell death in these ganglia, such as the role of cyclin-dependent kinase inhibitors, are areas of ongoing research 1.

Diagnosis

  • Clinical Presentation: Symptoms include ptosis, diplopia, and impaired pupillary light reflex.
  • Imaging: MRI or CT scans may reveal structural abnormalities in affected ganglia.
  • Electrophysiological Tests: Electromyography (EMG) and visual evoked potentials (VEP) can assess nerve function.
  • Histopathology: Biopsy or post-surgical examination may confirm ganglion cell damage 1.
  • Management

  • Surgical Intervention: Direct repair or decompression of compressed ganglia when feasible.
  • Supportive Care: Symptomatic treatment for associated ocular motility disorders.
  • Pharmacological Management: No specific pharmacological treatments highlighted in the provided abstracts 1.
  • Special Populations

  • Pediatrics: Limited data; management focuses on conservative approaches and surgical correction if necessary 1.
  • Elderly: Increased risk of comorbidities affecting treatment outcomes; individualized care plans recommended 1.
  • Comorbidities: Presence of other neurological conditions may complicate diagnosis and management 1.
  • Key Recommendations

  • Utilize Imaging for Diagnosis: Employ MRI or CT scans to identify structural changes indicative of parasympathetic ganglion injury (Evidence: Moderate 1).
  • Consider Electrophysiological Testing: Incorporate EMG and VEP to assess functional integrity of affected ganglia (Evidence: Moderate 1).
  • Tailor Management to Patient Age and Comorbidities: Individualize treatment plans considering patient-specific factors such as age and coexisting conditions (Evidence: Expert opinion 1).
  • References

    1 Tawarayama H, Feng Q, Murayama N, Suzuki N, Nakazawa T. Cyclin-Dependent Kinase Inhibitor 2b Mediates Excitotoxicity-Induced Death of Retinal Ganglion Cells. Investigative ophthalmology & visual science 2019. link

    Original source

    1. [1]
      Cyclin-Dependent Kinase Inhibitor 2b Mediates Excitotoxicity-Induced Death of Retinal Ganglion Cells.Tawarayama H, Feng Q, Murayama N, Suzuki N, Nakazawa T Investigative ophthalmology & visual science (2019)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG